Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Expanding MDS therapy options

Inga Mandac • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine

Inga Mandac, MD, Clinical Hospital Merkur, Zagreb, Croatia, tells us her personal highlights from this year’s meeting and the progression of the field in general. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Inga Mandac

2:51
MicroRNA signatures in MDS
Inga Mandac • 5 Mar 2020
1:12
Future MDS treatment options
Inga Mandac • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals